CORDIS
EU research results

CORDIS

English EN

A modular strategy for the repair of critical sized bone fractures

Project information

Grant agreement ID: 874889

Status

Ongoing project

  • Start date

    1 June 2020

  • End date

    31 May 2025

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 5 243 535,50

  • EU contribution

    € 5 243 535,50

Coordinated by:

UNIVERSITY OF GLASGOW

United Kingdom

Objective

Disruptive technologies for bone regeneration must be able to tackle complex fracture environments which have developed into non-union bone defects. These types of fracture are common and increasingly prevalent when considering the rise in osteoporosis cases. Bioengineered bone graft systems need to be able to guide the regrowth of new bone into substantial voids and therefore implants pre-seeded with mineralising cells are of significant clinical interest. We will implement a surgical co-administration of two robust technologies 1) a granular graft material with a highly osteogenic coating that presents relevant biologics very efficiently and 2) pre-differentiated osteogenic adipose mesenchymal stromal cells (MSCs) that together will underpin efficient bone regeneration. Within the project we aim to take these two technologies into GMP and ISO rated manufacture as required for any clinical therapy. We will then implement these therapies in pre-clinical studies to obtain efficacy and safety data to support a full clinical trial application. The novel technologies will be developed into a new medical device and a new cellular therapy with pre-clinical validation for their co-administration. This modular application of two highly advanced therapies is itself highly novel in terms of clinical strategy and by the end of the project we aim to have made the required regulatory and technical developments to submit them for clinical trial. In parallel to the core therapy we will expand the therapeutic pipeline by replacing the granular graft with 3D printed polymeric scaffold, again including including a highly osteogeneic coating, as a carrier for the cell therapy. Targeting even larger bone defects, this scaffold will be co-administered with the cellular therapy in pre-clinical efficacy studies.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITY OF GLASGOW

Address

University Avenue
G12 8qq Glasgow

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 845 706,75

Participants (4)

HISTOCELL SL

Spain

EU Contribution

€ 848 648,75

UNIVERSITY OF STRATHCLYDE

United Kingdom

EU Contribution

€ 461 405

UNIVERSIDAD DE NAVARRA

Spain

EU Contribution

€ 569 375

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 518 400

Project information

Grant agreement ID: 874889

Status

Ongoing project

  • Start date

    1 June 2020

  • End date

    31 May 2025

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 5 243 535,50

  • EU contribution

    € 5 243 535,50

Coordinated by:

UNIVERSITY OF GLASGOW

United Kingdom